Investigators tested whether an MYC-driven polyamine signature, as a liquid biopsy, is predictive of response to anti-CD19 CAR-T therapy in patients withrelapsed or refractory large B cell lymphoma.
[Cell Reports Medicine]
Home Newsletters Human Immunology News A Polyamine-Centric, Blood-Based Metabolite Panel Predictive of Poor Response to CAR-T Cell...
